title: Autoimmune thrombocytopenia related to chronic hepatitis C virus infection.
abstract: Since the identification of hepatitis C virus (HCV) in 1989 as a causative agent for a number of the extrahepatic alterations related to HCV infection an underlying immune mediated pathogenetic mechanism has been postulated. HCV-associated thrombocytopenia may be considered complex and multifactorial in origin, since different mechanisms have been implicated in its pathophysiology. With respect to autoimmune thrombocytopenia in chronic HCV infection, the detection of specific antibodies against platelet glycoproteins have been reported only in a few studies, but no systematic study has been carried out. We examined the clinical, laboratory, and virological characteristics of a case series of 10 patients with autoimmune thrombocytopenia (platelet count <150.0 x 10(9)/L) related to chronic HCV infection. Cases, six males and four females, aged 57.1 +/- 12.6 years, presented high titers of antibodies against platelet glycoprotein (GP) IIb/IIIa, GP Ia/IIa, and/or GP Ib/IX, and no other mechanism involved in the pathogenesis of HCV-associated thrombocytopenia was identified. Furthermore, cases were not associated with particular HCV genotype. Complete platelet response was observed in two patients treated with pegylated interferon plus ribavirin, and partial platelet response was seen in two patients treated with anti-D Ig and one patient treated with corticosteroids. These findings indicate that an autoimmune mechanism may play a role in the pathogenesis of HCV-associated thrombocytopenia in a proportion of these patients.
authors.affiliation: Viral Hepatitis Laboratory, Pav. Hélio & Peggy Pereira, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil. adilsonjoal@ig.com.br
authors.forename: A J
authors.initials: AJ
authors.lastname: de Almeida
authors.forename: M
authors.initials: M
authors.lastname: Campos-de-Magalhães
authors.forename: C L
authors.initials: CL
authors.lastname: Antonietti
authors.forename: C E
authors.initials: CE
authors.lastname: Brandão-Mello
authors.forename: M L P
authors.initials: ML
authors.lastname: da Silva
authors.forename: R V
authors.initials: RV
authors.lastname: de Oliveira
authors.forename: M P
authors.initials: MP
authors.lastname: do Espírito-Santo
authors.forename: C F T
authors.initials: CF
authors.lastname: Yoshida
authors.forename: E
authors.initials: E
authors.lastname: Lampe
mesh_terms: D000328:Adult; D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000097:blood / Q000821:virology*; D000906:Antibodies / Q000097:blood / Q000276:immunology; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D010980:Platelet Membrane Glycoproteins / Q000276:immunology; D011092:Polyethylene Glycols; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000906:Antibodies; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010980:Platelet Membrane Glycoproteins; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b